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Resumo 
 A degenerescência lobar frontotemporal (DLFT) é uma demência 
neurodegenerativa heterogénea, incluindo nos aspectos clínicos, neuropatológicos e 
genéticos. É caracterizada por mudanças progressivas no comportamento, disfunção 
executiva e/ou dificuldades na linguagem, acompanhada por atrofia no lobo frontal e 
temporal. Alguns doentes apresentam sobreposição clínica e neuropatológica com a 
doença de Alzheimer, o que sugere semelhanças na fisiopatologia, nomeadamente no 
envolvimento do DNA mitocondrial (mtDNA).  
O objetivo do presente estudo é realizar a sequenciação dos genes no mtDNA 
que codificam tRNAs, para identificar alterações nos doentes com DLFT, investigando 
o seu envolvimento na DLFT.  
Foram analisadas 70 amostras de DNA provenientes de doentes, 39 mulheres e 
31 homens, com diagnóstico provável de DLFT (faixa etária: 38-82 anos, média de 63 ± 
11), seguidos na Unidade de Neurologia do Centro Hospitalar e Universitário de 
Coimbra. O DNA total foi extraído a partir de sangue periférico, e foi efetuada a análise 
da sequência dos 22 genes de tRNAs mitocondriais, por sequenciação automática. As 
variantes encontradas foram submetidas a análise in silico. Foram encontradas 28 
variações diferentes em 32 doentes. Destas, seis variações são provavelmente 
patogénicas de acordo com a análise in silico: a m.4312C>T ocorre em  heteroplasmia e 
apresenta elevada conservação; a m.4435A>G está localizada numa posição 
potencialmente crítica e é totalmente conservada em todas as espécies analisadas; a 
variação m.5772G>A está localizada no T-stem, levando ao rompimento do 
emparelhamento da base (CG) Watson-Crick e é 100% conservada; a alteração 
m.12166T>C está localizada no “anticodon loop” e apresenta alta percentagem de 
conservação. A variação mais frequente é a m.12308A>G, no mt-tRNALeu2,na região 
variável, e é totalmente conservada em todos os mamíferos estudados. A variação 
m.15946C>T tem uma elevada taxa de conservação e está localizada no “acceptor 
stem”. São necessários estudos adicionais para compreender melhor a relação entre as 
alterações do mtDNA identificadas e a FTLD. No entanto, este estudo é original sendo 
o primeiro a investigar a sequencia dos genes que codificam os tRNA mitocondrias na 
DLFT. 
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1. General Introduction  
 
1.1. Dementia 
 
In the last years, life expectancy has increased at a steady rate, which leads to an 
increment the percentage of elderly in the population (Santana and Cunha, 2005). The 
decline in mortality and births results in aging of the population in most developed 
countries and, consequently, the prevalence of age-related diseases, including 
dementias, are increasing. Dementia syndromes are characterized by progressive 
impairment in cognitive function and they have become increasingly important in public 
health (Fratiglioni et al., 1999). Among the various dementias, Alzheimer's disease 
(AD) and Frontotemporal Lobar Degeneration (FTLD) are the most frequent in the 
population (Santana and Cunha, 2005). 
 
1.2. FTLD History 
 
In 1892, Arnold Pick described the first clinical case of dementia, in which the 
patient presented cognitive impairment, progressive aphasia and changes in social 
behaviour. These manifestations are associated with temporal and frontal lobe atrophy 
(Kertesz et al., 2005). In 1911, Alois Alzheimer described the histopathology features of  
these patients, pointing to the presence of argyrophilic neuronal inclusions, later called 
“Pick bodies” (Pan and Chen, 2013). A century later, research groups of Lund (Sweden) 
and Manchester (England) published the first clinical and neuropathological criteria set 
for the diagnosis of frontotemporal dementia (FTD) (Lund and Manchester Groups, 
1994). 
 
1.3. FTLD Epidemiology  
 
FTLD is a heterogeneous neurodegenerative dementia in many aspects, 
including clinical, neuropathological and genetic features, characterized by progressive 
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changes in behaviour, executive dysfunction and/or language impairment (Seltman and 
Matthews, 2012) with frontal and temporal lobar atrophy (Pan and Chen, 2013). FTLD 
occurs most often in the presenile period, with age at onset typically at 45-65 years, and 
it has an equal distribution among female and male (Galimberti and Scarpini, 2010). 
There is a wide range in duration of illness (2-20 years) partly reflecting different 
underlying pathologies (Seelaar et al., 2011). 
 
1.4. Clinical variants of FTLD 
 
Given its heterogeneity, FTLD is classified differently regarding the clinical 
characteristics. The site of focal cerebral atrophy, frontal and/or temporal, left and/or 
right determines the clinical presentation (Schlachetzki, 2011). It can be differentiated 
clinically into three frontotemporal dementia (FTD) syndromes; clinically behavioural 
variant (bvFTD), characterized by progressive behavioural impairment and a decline in 
executive function with frontal lobe atrophy; progressive nonfluent aphasia (PNFA) 
with motor speech deficits and semantic dementia (SD) with loss of object knowledge 
with anomia (Seltman and Matthews, 2012). Language variants are subsumed under the 
clinical syndrome of primary progressive aphasia (PPA) and show involvement of the 
left anterior temporal lobe (Schlachetzki, 2011). Additionally, there is a clinical overlap 
between FTD with motor neuron disease (FTD-MND or FTD-ALS), as well as the 
parkinsonian syndromes, progressive supranuclear palsy (PSP) and corticobasal 
syndrome (CBS) (Pan and Chen, 2013). 
 
1.5. FTLD Neuropathological variants  
 
The neuropathology underlying the FTLD clinical syndromes is also 
heterogeneous (Boxer et al., 2011). While clinical phenotype, neuropsychology features 
and brain imaging data provide useful information about the FTLD spectrum pathology, 
additional information is necessary to define the histopathological abnormality in 
patients, since a clinical phenotype can be associated with several different pathologies 
(Grossman, 2011). The major pathological hallmark of FTLD is selective atrophy of the 
frontal and temporal cortex, with neuronal loss and gliosis (Seelaar et al., 2011). In most 
cases, it is possible to find an accumulation of abnormal proteins in neurons and glia 
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(inclusions of aggregates). The identity of the pathological protein is variable (Boxer at 
al., 2011) and the classification has been changing in the last few years.  The currently 
accepted nomenclature for the various FTLD neuropathological subtypes considers into 
five groups, FTLD-tau (tau pathology), FTLD-TDP (TAR-DNA binding protein (TDP-
43)), FTLD-UPS (ubiquitin-positive and TDP-43-negative histopathology), FTLD-FUS 
(inclusions of the fused in sarcoma protein) and FTLD-ni (without inclusions) 
(Mackenzie et al., 2010). It was found that there is a correlation between 
neuropathological characteristics and genetic mutations (Table I). 
 
Table I: Neuropathological characterization of FTLD and associated genes 
(adapted from Mackenzie et al., 2010) 
FTLD with tau-negative and ubiquitin-positive 
FTLD-tau 
FTLD-TDP FTLD-FUS FTLD-UPS 
FTLD-ni 
Mutation in the 
gene MAPT 
Mutation in genes 
GRN 
VCP 
TARDBP 
C9ORF72 
Mutation in the 
gene FUS 
Mutation in the 
CHMP2B 
No known 
mutations 
 
 
About 40% of FTLD cases are FTLD-tau, including all cases of FTLD with 
MAPT mutations. The most frequent FTLD pathology cases are characterized by tau-
negative and ubiquitin-positive inclusions the FTLD-TDP, patients have mutations in 
GRN, TARDBP, VCP or C9ORF72 genes; CHMP2B cases show ubiquitin-positive 
inclusions; TDP-43 negative histopathology (FTLD-UPS) and many of the ubiquitin-
positive, TDP-43- negative cases have been show to have FTLD-FUS. However, the 
majority of these patients do not harbour mutations in FUS gene (Goldman et al., 2011). 
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1.6. Genetic variants of FTLD 
 
Positive family history was observed in 40-50% of the FTLD patients (Sieben, et 
al., 2012). The autosomal dominant mode of inheritance has been described in 10-27% 
of all FTLD patients with mutations identified. The familial cases are more common as 
bvFTD and less frequent in patients with SD and PNFA. The genetic heterogeneity of 
FTLD is reflected by the identification of mutations in several nuclear genes. The most 
common mutations occur in the GRN and MAPT genes in approximately 50% of the 
familial cases, while more rare mutations occur in the CHMP2B, FUS, VCP and 
TARDBP genes (Seelaar et al., 2011). Recently, a gene responsible for FTLD has been 
discovered on chromosome 9p (C9ORF72). More than 40 pathogenic MAPT mutations 
have been described in 134 families and 69 different mutations in GRN gene have been 
described in 231 families (Galimberti e Scarpini, 2012) (Table II). 
 
    Table II: Genetic characterization of FTLD (adapted from Schlachetzki, 2011) 
Gene Chromosome Protein 
MAPT 17q21.1 Microtubule associated protein tau 
GRN 17q21.31 Progranulin 
VCP 9p13.3 Valosin-containing protein 
TARDBP 1p36.2 TAR DNA-binding protein TDP-43 
CHMP2B 3p11.2 Charged multivesicular  body protein 2B 
FUS 16p11.2 Fused in sarcoma protein 
C9ORF72 9p13.2-21.3 Not determined  
 
 
1.7. Etiological mechanisms of FTLD 
 
Some FTLD patients present a clinical and neuropathological overlap with AD. 
This event may suggest similarities in pathophysiology, including the involvement of 
mitochondrial DNA (mtDNA) in FTLD (Grazina et al., 2004), as it has been observed 
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in AD (Onyango et al., 2006). There are several studies that have identified mtDNA 
mutations in AD patients, suggesting the existence of causal factors related to mtDNA. 
This points to the involvement and contribution of mitochondrial genome to dementia 
(revision Grazina et al., 2006). Accordingly, it is important to study the role of mtDNA 
in FTLD (Grazina et al,. 2004). 
 
1.8. Mitochondrial DNA study in FTLD 
 
A number of essential cellular functions take place in the mitochondria. 
However, the major mitochondrial event is the production of adenosine -5`-triphosphate 
(ATP), the key energy source of the cell (Morán et al., 2012). Mitochondrial ATP is 
generated via oxidative phosphorylation (OXPHOS), that occurs in the mitochondrial 
respiratory chain (MRC), located within the inner mitochondrial membrane (Reddy, 
2008). The process of OXPHOS system comprises five multiprotein complexes. Each 
OXPHOS complex consists of polypeptide subunits encoded by nuclear and 
mitochondrial DNA, except complex II, which is exclusively encoded by the nuclear 
genome (Grazina, 2004). The correct biosynthesis of the OXPHOS complexes is a 
highly intricate regulated process that requires the concerted action of the two cellular 
genomes (Morán et al., 2012). Human mtDNA consists of a 16,568 nucleotides 
organized in a double stranded, circular DNA molecule, containing 37 genes, encoding 
for 12S and 16S rRNA, 22 tRNAs and 13 polypeptides , essential components of the 
MRC (Reddy, 2008). The 2 rRNA, 14 tRNAs and 12 proteins are encoded on the heavy 
strand (HS), while 8 tRNAs and 1 protein are encoded on the light strand (LS) (Clayton, 
1984) (Figure I). The remaining mitochondrial factors are encoded by nuclear genome 
and are subsequently transported into the mitochondria (Nicholls et al., 2013), including 
the proteins involved in mt-RNA metabolism.   
The mitochondrial genome has its own genetic code, is regulated semi-
autonomously, which depends on the replication and transcripton factors of nuclear 
origin, being the essential regulatory sequences located at the D-loop (non-coding 
region of the mitochondrial genome). DNA replication is bidirectional, starts from the 
origin of replication of HS (OH), located in the D-loop going clockwise, to allow the 
synthesis of HS. After, the replication of LS begins, in the opposite direction of the HS 
replication. Moreover, mtDNA transcription results in an asymmetrical way, as the two 
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chains promoters, heavy strand promoter (PH) and light strand promoter (PL) are both 
located on the D-loop. The two promoters work in opposite directions, and HS is 
transcribed in the opposite to clockwise direction (Grazina, 2004). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I: Human mitochondrial DNA (adapted from Greaves et al., 2012). ND1 –
NADH dehydrogenase, subunit 1;  ND2 – NADH dehydrogenase, subunit 2; ND3 – NADH 
dehydrogenase, subunit 3; ND4 – NADH dehydrogenase, subunit 4; ND4L – NADH dehydrogenase, 
subunit 4L; ND5 – NADH dehydrogenase, subunit 5; ND6 – NADH dehydrogenase, subunit 6; CYTB – 
Cythocrome B; COI – cytochrome c oxidase I; COII – cytochrome c oxidase II; COIII – cytochrome c 
oxidase III; ATP6 – ATP synthase F0 subunit 6; ATP8 –  ATP synthase F0 subunit 8; RNR1 – 
Mitochondrially encoded 12S RNA; RNR2 – Mitochondrially encoded 16S RNA; T - Mitochondrially 
encoded tRNA threonine; P - Mitochondrially encoded tRNA proline; E - Mitochondrially encoded tRNA 
glutamic acid; L2 - Mitochondrially encoded tRNA leucine 2; S2- Mitochondrially encoded tRNA serine 
2; H- Mitochondrially encoded tRNA histidine; R- Mitochondrially encoded tRNA arginine  ; G- 
Mitochondrially encoded tRNA glycine; K- Mitochondrially encoded tRNA lysine; D- Mitochondrially 
encoded tRNA aspartic acid; S1- Mitochondrially encoded tRNA serine 1;  Y- Mitochondrially encoded 
tRNA tyrosine ; C-Mitochondrially encoded tRNA cysteine; N-Mitochondrially encoded tRNA 
asparagines; A- Mitochondrially encoded tRNA alanine; W- Mitochondrially encoded tRNA tryptophan; 
M- Mitochondrially encoded tRNA methionine: I- Mitochondrially encoded tRNA isoleucine; Q- 
Mitochondrially encoded tRNA glutamine; L1- Mitochondrially encoded tRNA leucine 1; V- 
Mitochondrially encoded tRNA valine; F-  Mitochondrially encoded tRNA phenylalanine. 
 
 
Most human cells contain hundreds of mitochondria and thousands of mtDNA 
copies. This genome is transmitted by maternal inheritance. Due to this fact, maternal 
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and paternal mtDNAs are rarely mixed in the same cytoplasm, not having 
recombination between the two types of mtDNA. The only way that mtDNA sequence 
may change is through the accumulation of mutations along the maternal lineage. The 
high mutation rate of mtDNA results from the lack of protective histones, and 
inefficient mtDNA repair systems (Wallace, 1994). In the OXPHOS process, besides 
ATP synthesis, there is also the reactive oxygen species (ROS) production and mtDNA 
is located close to the main source of ROS formation, being vulnerable to damage 
(Reddy and Reddy et al., 2011). The first mtDNA pathogenic mutations were identified 
in the late 1980s. Since then, more than 200 mutations in mtDNA were found 
(Chinnery, 2006). When there is a mtDNA mutation, a mixture of wild and mutant 
molecules could coexist and this situation is called heteroplasmy; on the other hand, the 
presence of pure wild or pure mutant molecules are called homoplasmy. In case of 
heteroplasmy, as the percentage of mutant molecules increases, oxidative 
phosphorylation enzyme activities decrease. When the energy threshold is reached, the 
probability of disease manifestation becomes higher (Wallace, 1994). The percentage of 
mutated DNA may vary in different patients, from organ to organ and even between 
cells within of the same tissue (Chinnery, 2006). 
Mitochondrial changes, including MRC dysfunction due to enzymatic defects, 
increases ROS production. Morphological changes in the mitochondrial network and 
cell death are common features of neurodegenerative diseases of different genetic 
origins. Mutations in genes encoding proteins involved in mitochondrial dynamics were 
identified in neurodegenerative diseases (Móran et al., 2012).  
 
1.9. Human Mitochondrial tRNAs 
 
Mitochondrial genome encodes 22 tRNAs (tRNAPhe , tRNAVal, tRNALeu1 , 
tRNAIle, tRNAGln, tRNAMet, tRNATrp, tRNAAla, tRNAAsn, tRNACys, tRNATyr, tRNASer1, 
tRNAAsp, tRNALys, tRNAGly, tRNAArg, tRNAHis, tRNASer 2, tRNALeu 2, tRNAGln, tRNAThr 
and tRNAPro), essential to intramitochondrial protein synthesis. Amino acids are added 
to the protein during translation, by transfer RNAs. Each tRNA molecule is encoded by 
a different gene and its transcriptional nucleotide sequence results in a pre-tRNA that is 
organized into a characteristic secondary structure. This structure, common to the pre-
tRNA and tRNA, is clover-shaped due to the hydrogen bonds established between 
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complementary bases (Cooper and Hausman, 2007). The tRNA is composed by 
acceptor stem, D-stem, D-loop, anticodon stem, anticodon loop, variable region, T-loop 
and T-stem (Suzuki et al., 2011), as presented in Figure II. 
 
 
 
 
 
 
 
 
Figure II: Structure of a mt-tRNA (adapted from Yarham et al., 2011). 
The pre-tRNA processing leads to their maturation into RNA and its activation. 
The processing of mitochondrial tRNAs requires precise endonucleolytic cleavage at 
both 5` and 3` ends. Excision of tRNAs is catalyzed by two specialized enzymes 
(Levinger et al., 2004), RNase P (the tRNA 5´ end processing endonuclease) and 
tRNase Z (the tRNA 3´ end processing endonuclease). After excision, pre-tRNA 3` ends 
are subsequently completed by the addition of the “CCA” triplet through an ATP (CTP) 
– tRNA-specific nucleotidyltransferase activity (Rossmanith et al.,1995) necessary for 
amino acid attachment and proper tRNA positioning at the ribosome (Nicholls et al., 
2013). Once the tRNA is synthesized, the fidelity of protein synthesis depends on the 
specific attachment of amino acid to its specific tRNA. This process is catalyzed by 
aminoacyl-tRNA synthetases (aaRS) (Suzuki et al., 2011). The human genome encodes 
one enzyme per amino acid. The tRNAs are subsequently carried to the ribosome by 
translation factor elongation factor (EF)-Tu, allowing protein synthesis (Levinger et al., 
2004), as presented in Figure III. 
The encoding system in mitochondrial genome is different from the universal 
genetic code because of the use of “AUA” for Met, “UGA” for Trp and “AGR” R = A 
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and G) as stop signal (Suzuki et al., 2011). The genetic mtDNA code has sixty codons 
for the 22 mt-tRNAs (Suzuki et al., 2011), as presented in (Table III). 
 
Figure III: The tRNA end processing pathway followed by aminoacylation (adapted 
from Levinger et al., 2004). 
  
 
Table III: Human mitochondrial genetic code (from Suzuki et al., 2011). 
 
 
From the approximately 400 mutations with possibly pathogenic character found 
in mtDNA, about the half are located in mt-tRNA genes (MITOMAP, 2013). These 
genes are highly susceptible to point mutations, which are one of the main causes of 
mitochondrial dysfunction associated with a variety of diseases (Levinger et al., 2004). 
Mutations in mt-tRNAs can affect a large variety of mechanisms, including 
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transcription, maturation, post-transcriptional modification, structure, stability, 
aminoacylation, capability of binding to elongation factor EF-Tu and codon reading 
(Zhang et al., 2011). 
Due to the central role in protein synthesis, the malfunction of mutant tRNAs 
can play a key role in mitochondrial diseases. Disorders related to mitochondrial tRNAs 
have been associated with several clinical phenotypes, including encephalopathies, 
myopathies, myoclonus, ophthalmoplegia, heart disease, deafness and others (Levinger 
et al., 2004). Changes in mitochondrial genes encoding tRNAs have also been described 
in neurodegenerative diseases such as AD and Parkinson’s disease (Egensperger et al., 
1997; Hutchin et al., 1997; Grasbon-Frodl et al., 1999; Edland et al., 2002). Since there 
is no previous investigation of the involvement of mt-tRNAs encoding genes in FTLD, 
it is important to study their contribution to this pathology. 
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Abstract  
 
FTLD is a heterogeneous neurodegenerative dementia in many aspects, 
including clinical, neuropathological and genetic features, characterized by progressive 
changes in behaviour, executive dysfunction and/or language impairment. It is 
characterized by progressive changes in behaviour, executive dysfunction and/or 
language impairment with frontal and temporal lobar atrophy. Some patients present 
clinical and neuropathological overlap with Alzheimer's disease, suggesting similarities 
in pathophysiology, including mitochondrial DNA (mtDNA) involvement. 
The aim of the study includes sequencing the 22 tRNAs genes encoded in 
mtDNA for identifying variations in FTLD patients, ascertaining their involvement in 
FTLD. 
We investigated 70 patients, 39 females and 31 males with probable diagnosis of 
FTLD (age range: 38-82 years, mean 63 ± 11), recruited at Neurology Unit of the 
Centro Hospitalar e Universitário de Coimbra. Total DNA was extracted from 
peripheral blood and analysis of 22 tRNA mtDNA encoded genes sequences was 
performed by automated DNA Sanger sequencing and variants were submitted to in 
silico analysis. A total of 28 different sequence variations were identified in 32 patients 
(46%). From these, 6 variations are probably pathogenic, according to the in silico 
analysis, all causing structure and binding minimum free energy changes: m.4312C>T 
is heteroplasmic and presents and high percentage of conservation; m.4435A>G is in a 
critical position and is totally conserved in all species studied; The m.5772G>A is 
located in T-stem and leads to the disruption of Watson–Crick base pairing (C-G), being 
100% conserved in all species; m.12166T>C alteration is in anticodon loop and has 
high percentage of conservation. The most frequent variation found is m.12308A>G, in 
the variable region of mt-tRNALeu2 and it is totally conserved in all mammals tested; 
m.15946C>T variation has a high rate of conservation and it is located in the acceptor 
stem. Further investigation is needed to better understand the relationship between 
mtDNA alteration found and FTLD, considering also the involvement of nuclear genes 
in this disorder. However, this is an original study, being the first to investigate the 
sequence of the tRNA genes encoded by mtDNA in FTLD. 
Keywords: mitochondrial DNA; FTLD; mt-tRNA genes; sequence variations. 
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Introduction 
 
Frontotemporal lobar degeneration (FTLD) is a heterogeneous 
neurodegenerative dementia, in many aspects, including clinical, neuropathological and 
genetic features. It is characterized by progressive changes in behaviour, executive 
dysfunction and/or language impairment (Seltman and Matthews, 2012) with frontal 
and temporal lobar atrophy (Pan and Chen, 2013). FTLD occurs most often in the 
presenile period and the age of onset is typically at 45-65 years, and it has an equal 
distribution among men and women (Galimberti and Scarpini, 2010). There is a wide 
range in durations of illness (2-20 years), partly reflecting different underlying 
pathologies (Seelaar et al., 2011). The FTLD clinical spectrum encompasses three 
distinct syndromes: the behavioural variant (bvFTD) characterized by progressive 
behavioural impairment and a decline in executive function; progressive nonfluent 
aphasia (PNFA), with motor speech deficits; and semantic dementia (SD), with loss of 
object knowledge with anomia (Seltman and Matthews, 2012). Additionally, there is a 
significant clinical overlap between FTD with motor neuron disease (FTD-MND or 
FTD-ALS), as well as the parkinsonian syndromes, progressive supranuclear palsy 
(PSP) and corticobasal syndrome (CBS) (Pan and Chen, 2013). Neuropathology 
classification of includes five groups: FTLD-tau (tau patology); FTLD-TDP (TAR-
DNA binding protein, TDP-43), FTLD-UPS (ubiquitin-positive and TDP-43-negative 
histopathology); FTLD-FUS (inclusions of the “fused in sarcoma protein”) and FTLD-
ni (without inclusions) (Mackenzie et al., 2010). Positive family history is observed in 
40-50% of the FTLD patients (Sieben, et al., 2012). The autosomal dominant mode of 
inheritance is found in 10-27% of all FTLD patients. The genetic heterogeneity of 
FTLD is reflected by the identification of mutations in several nuclear genes, associated 
with different neuropathological subjects. The most common mutations occur in GRN 
and MAPT genes, in approximately 50% of familial cases, while more rare mutations 
occur in CHMP2B, FUS, VCP, TARDBP and C9ORF72 genes (Seelaar et al., 2011). 
Some FTLD patients present a clinical and neuropathological overlap with AD. This 
event may suggest similarities in pathophysiology, including the involvement of 
mitochondrial DNA (mtDNA) in FTLD (Grazina et al., 2004; Grazina et al., 2006), as it 
has been observed in AD (Onyango et al., 2006). For this reason, it is important to study 
the role of mtDNA in FTD. Mitochondrial changes, including mitochondrial chain 
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respiratory (MRC) dysfunction due to enzymatic defects, increased ROS production. 
Morphological changes in the mitochondrial network and cell death are common 
features of neurodegenerative diseases of different genetic origins. Mutations in genes 
encoding proteins involved in mitochondrial dynamics were identified in 
neurodegenerative diseases (Móran, 2012). Human mtDNA consists of a 16,568 
nucleotides organized in a double stranded, circular DNA molecule, containing 37 
genes, encoding for 12S and 16S rRNA, 22 tRNAs and 13 polypeptides, essential 
components of the MRC (Reddy, 2008). The present work includes the study of the 22 
tRNAs encoded by mtDNA, essential for intramitochondrial protein synthesis. From the 
400 mutations with possibly pathogenic character found in mtDNA, approximately are 
belongs to mt-tRNA genes (MITOMAP, 2013). These genes highly susceptible to point 
mutations, which are one of the main causes of dysfunction mitochondrial associated 
with a variety of diseases. Due to the central role in protein synthesis, the malfunction 
of mutant tRNAs could be important in the pathologies occurring in mitochondria. 
Disorders related to mt-tRNA have been associated with several clinical phenotypes, 
including encephalopathies, myopathies, myoclonus, ophthalmoplegia, heart disease, 
deafness, and others (Levinger et al., 2004). Changes in mitochondrial genes encoding 
tRNAs have also been described in neurodegenerative diseases such as AD and 
Parkinson`s disease (Egensperger et al., 1997; Hutchin et al., 1997; Grasbon-Frodl et 
al., 1999; Edland et al., 2002). Since there is no previous investigation of the 
involvement of mt-tRNAs encoding genes in FTLD, it is important to study their 
contribution to this pathology.  
 
Objectives  
This study aims to investigate the sequence of 22 mtDNA encoded tRNA genes 
for identifying variations in FTLD patients, ascertaining their involvement in FTLD. 
 
Patients and Methods 
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Samples 
DNA samples of 70 patients (39 females and 31 males; age range: 38-82 years, 
mean 63 ± 11) with probable diagnosis of FTLD according to the standard criteria of 
DSM-IV ( Brun et al., 1994; McKhann et al.,2001) recruited at Neurology Unit of the 
Centro Hospitalar e Universitário de Coimbra were investigated.  
Total DNA was extracted from peripheral blood by standard phenol chloroform method 
(Treco, 1999). 
 The scaling of the dementia was obtained by scoring, the CDR (Clinical 
Dementia Rating) and MMSE (Mini–mental state examination). In CDR, the scale is 
between 0 and 3 and the higher values correspond to higher degree of dementia. In 
MMSE, the scale is between 0 and 30 and lower values correspond to higher degree of 
dementia (Folstein et al., 1975) 
 
PCR amplification 
 
Amplification of the 22 mitochondrial tRNA enconding genes was performed by 
Polymerase Chain Reaction (PCR). This technique allows obtaining multiple copies of a 
particular DNA fragment. The amplification conditions included initial denaturation at 
95°C for 5 min followed by 35 cycles at 95°C for 45 s, 50-60ºC for 45 s, 72°C for 60 s, 
and a final extension step at 72°C for 5 min using a master mix containing 2-10 ng of 
DNA, 10X buffer, dNTP (2mM), primer forward (2,5µM), primer reverse (2,5µM), Taq 
DNA polymerase, H2O milli Q and MgCl2 (Landsverk et al., 2012). 
 
Agarose gel electrophoresis 
 
PCR procedure was followed by agarose gel electrophoresis for the separation of 
DNA fragments, in order to verify the success of amplification. PCR products were 
mixed with loading dye (1:1) and then applied to 1% agarose gel for 1 hour, at 100 
Volts, using weight marker. After migration, ethidium bromide labeled DNA molecules 
were visualized under ultraviolet irradiation (Landsverk et al., 2012). 
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DNA Sanger Sequencing 
 
 After PCR product analysis, samples were purified with ExoSAP-IT®, consisting 
of exonuclease I (exo I) and alkaline phosphatase (SAP) to degrade the excess of 
primers and nucleotides, which are the main factors interfering with PCR sequencing 
(Werle et al., 1994).  
The sequencing PCR involves the synthesis of single stranded DNA using the 
DNA previously amplified in PCR as template. Synthesized chains are terminated 
prematurely with various possible sizes. The synthesis begins at the primer binding site 
and ending with the incorporation of a terminator nucleotide that lack the hydroxyl 
group at the 3' position of the deoxyribose, preventing the establishment of connections 
phospho-diester and the incorporation of new nucleotides to DNA strand. When a 
terminator nucleotide is incorporated, the synthesis of new chain ends (Buitrago and 
Jimenez, 2001). The amplification conditions were an initial denaturation at 96°C for 2 
min followed by 45 cycles at 96°C for 10 s, 55ºC for 5 s, 60°C for 4 min, using 
BigDye® Terminator Ready Reaction Mix v3.1, 5X sequencing buffer, 2,5µM of 
primer forward or reverse and H2O milli Q (Landsverk et al., 2012). 
After sequencing PCR, samples were submitted to standard Sephadex® 
purification (gel filtration), which removes substances which have not been added 
during the reaction. After purification, the samples were loaded in the sequencer ABI 
Prism® 3130 (Applied Biosystems). 
This is a fast and automated process that allows the determination of nucleotide 
sequence comprising the DNA fragment to be studied (Buitrago and Jimenez, 2001). 
Automated DNA Sequencing is based on electrophoretic procedures using polymer 
gels. Applied Biosystems DNA sequencers detect fluorescence from four different dyes 
that are used to identify the A, C, G and T terminators. Each dye has a fluorescence 
wavelenght when excited by argon ion laser, allowing detection and distinction of all 
four bases. 
After the automated sequencing, samples sequences were analysed using 
Sequencing Analysis v5.4® and SeqScape v2.5® software, which allow to compare the 
obtained data with the reference sequence. Thus, it is possible to detect any variation in 
the sequence under study. 
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In silico analysis  
 
After the analysis of all sequences, an in silico study of the detected changes was 
performed, using different databases such as MITOMAP where the variations are 
reported (MITOMAP, 2013), RNAfold (Hofacker et al., 1994) that predict the RNA 
secondary structure based on minimum energy requirements and pair probabilities 
(Mezghani et al., 2011). The localization of the sequence variations in mt-tRNA and 
sequences from the species were obtained from the Mamit-tRNA database (Putz et al., 
2007). Evolutionary conservation was performed for all alterations (12 mt-tRNAs) in 10 
different species (Homo sapiens, Pan paniscus, Pan troglodytes, Gorilla gorilla, Pongo 
pygmaeus, Macaca mulatta, Bos taurus, Canis familiaris, Mus musculus, Rattus 
norvegicus). The sequence alignment of the mt-tRNAs was performed using the 
ClustalW® software (Sievers et al., 2011). In 2004, the first criteria applied to particular 
the mutations in mt-tRNA have been created (MacFarland et al., 2004).  Subsequently, a 
comparison of various forms of evaluation criteria scoring systems are use to increase 
the accuracy of assignment of pathogenicity. (Yarham et al., 2011). 
Table 1: The Pathogenicity Scoring System (from Yarham et al., 2011) 
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Results 
A total of 70 patients (39 females and 31 males) with FTLD were included in 
this study.  
From these, 32 (17 females and 15 males) present 28 different genetic variations 
in mt-tRNA genes. We have found 22 patients with only one variation, 9 patients with 2 
variations and 3 patients with 4 variations. Patients 5, 43 and 51 have the higher number 
of variations (Table 2).  
Concerning the CDR, 15 patients presented the maximum degree of dementia 
but only 5 of these have mtDNA variations. The remaining patients presented moderate 
or mild dementia. For MMSE, 10 patients exhibited maximum degree of dementia but 
only 4 of these present variations (Table 3). 
From the 28 different genetic variations, there are 19 variations that were 
identified only in 1 patient, 4 variations twice, 3 variations three times, 1 variation four 
times and other variation tenfold. Only 12 mt-tRNAs have variations identified 
(tRNAAla, tRNAIle, tRNAMet, tRNAHis, tRNAThr, tRNAGln, tRNACys, tRNAGly, tRNALeu2, 
tRNAVal, tRNAArg and tRNAAsp), as presented in Figure 1. 
The variations identified were found in MITOMAP database: 14 have been 
described as “polymorphism”, 8 as “polymorphism” and “mutation”; 3 variations as 
“polymorphism” and “somatic mutation”; 1 as “mutation”; 1 variation as 
“polymorphism” and “mutation”; and 1 “novel” (m.7567C>A). The minimum free 
energy was changed in 22 of the 28 found sequence variations but 5 (m.5775T>C, 
m.7521G>A, m.10410T>C, m.12192G>A and m.15927G>A) of these are not predicted 
to alter the tRNA structure. Concerning the location of the variations in mt-tRNAs 
structure, 14 were found in the stems, 10 in the loops and 4 in the variable region (Table 
3). 
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Figure 
1: Number of alteration per gene in which they were identified. 
There are 6 variations probably pathogenic, according to the in silico analysis, 
all causing structure and binding minimum free energy changes: m.4312C>T is 
heteroplasmic and presents and high percentage of conservation (Figure 2); m.4435A>G 
is in a critical position and is totally conserved in all species studied (Figure 3) ; The 
m.5772G>A is located in T-stem and leads to the disruption of Watson–Crick base 
pairing (C-G), being 100% conserved in all species (Figure 4); m.12166T>C alteration 
is in anticodon loop and has high percentage of conservation (Figure 5). The most 
frequent variation found is m.12308A>G, in the variable region of mt-tRNALeu2 and it is 
totally conserved in all mammals tested (Figure 6); m.15946C>T variation has a high 
rate of conservation and it is located in the acceptor stem (Figure 7). 
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 Table 2: Patients characterization and data from mtDNA sequence variations.  
Patient Clinical 
Variant 
Gender Age Age of 
Onset 
CDR MMSE mtDNA Sequence 
variation Gene 
1 bvFTD F 53 52 3 0 m.5633C>T tRNAAla 
2 bvFTD F 65 64 3 11  
 
3 bvFTD F 74 73 1 17  
 
4 CBS M 54 53 3 0  
 
tRNAIle 
tRNAMet 5 bvFTD M 67 59 1 27 
m.4312C>T(Het)                              
m.4318 C>T(Het)                                
m.4456C>T(Het)                        
m.12184A>G tRNAHis 
6 CBS F 58 58 1 18  
 
7 bvFTD M 45 40 3 7  
 
8 bvFTD M 43 43 2 16  
 
9 bvFTD M 58 44 3 6  
 
10 bvFTD F 54 53 2 18  
 
11 bvFTD F 69 69 1 19  
 
12 bvFTD F 59 53 3 0  
 
13 bvFTD F 75 72 1 20  
 
14 bvFTD F 71 68 2 12 m.15927G>A tRNAThr 
15 SD M 46 41 3 10 m.12179A>G tRNAHis 
16 bvFTD F 64 63 1 25 m.15904C>T tRNAThr 
17 bvFTD F 59 55 3 0 m.4336T>C tRNAGln 
18 bvFTD F 75 74 1 27  
 
19 PPA M 60 58 3 9  
 
20 bvDFT F 55 54 1 22 m.12308A>G tRNALeu2 
21 bvFTD F 77 73 3 10  
 
22 bvFTD F 46 43 1 22  
 
tRNACys 23 bvFTD F 81 79 1 21 m.5772G>A                      
m.15904C>T tRNAThr 
tRNAGly 24 bvFTD M 61 56 2 12 m.10034T>C                        m.15924A>G tRNAThr 
25 bvFTD M 66 63 1 29 m.15930G>A tRNAThr 
26 bvFTD M 75 64 1 27  
 
27 bvFTD F 62 59 2 17  
 
28 bvFTD F 74 69 2 15  
 
29 bvFTD F 74 72 1 15 m.12308A>G tRNALeu2 
30 PPA F 49 48 1 30 m.12308A>G tRNALeu2 
31 bvFTD M 64 62 0.5 28  
 
tRNALeu2 32 bvFTD F 50 50 2 17 m.12308A>G                           
m.15924A>G tRNAThr 
33 bvFTD F 60 56 1 15  
 
34 bvFTD M 64 60 1 22 m.12308A>G tRNALeu2 
35 bvDFT F 71 67 3 14  
 
36 SD M 54 52 1 21  
 
37 bvFTD F 65 63 3 1 m.15905T>C tRNAThr 
 Isabel Oliveira Page 22 
 
Table 2: Patients characterization and data from mtDNA sequence variations (cont). 
38 bvFTD F 49 48 0.5 30  
 
tRNAHis 39 bvFTD F 59 57 1 18 m.12166T>C                            
m.15927G>A tRNAThr 
40 bvFTD F 54 50 2 19  
 
41 bvFTD M 51 51 1 25 m.4435A>G tRNAMet 
42 bvFTD M 68 67 1 27 m.5633C>T tRNAAla 
tRNAVal 
tRNAVal 
tRNAGly 43 bvFTD M 76 70 1 28 
m.1640A>G 
m.1659T>C 
m.10034T>C 
m.15928G>A tRNAThr 
44 bvFTD M 64 61 1 24 m.15924A>G tRNAThr 
45 bvFTD F 68 66 2 15  
 
tRNAArg 46 bvFTD M 70 69 1 20 m.10463T>C                             
m.15908T>C tRNAThr 
47 bvFTD F 66 60 3 16  
 
48 bvFTD M 59 56 1 21  
 
49 bvFTD M 74 73 2 16 m.15904C>T tRNAThr 
50 bvFTD F 54 54 1 26 m.5775T>C tRNACys 
tRNAAsp 
tRNAGly 
tRNAArg 51 bvFTD F 59 58 2 16 
m.7567C>A                             
m.10034T>C                                
m.10410T>C                          
m.12192G>A tRNAHis 
52 bvDFT F 78 78 1 28 m.15904C>T tRNAThr 
53 bvFTD F 48 47 3 0  
 
54 bvFTD F 82 78 1 20  
 
55 bvFTD M 73 73 1 28  
 
56 CBS M 43 42 1 22 m.12308A>G tRNALeu2 
57 bvFTD M 38 34 1 25  
 
58 bvFTD M 72 69 2 13 m.7521G>A tRNAAsp 
59 bvFTD F 81 75 2 13  
 
tRNALeu2 
60 PPA F 69 56 1 13 m.12308A>G                            
m.14956C>T tRNAThr 
61 PPA F 65 62 3 4 m.12308A>G tRNALeu2 
62 bvFTD M 65 63 0.5 29  
 
tRNALeu2 63 bvFTD M 71 68 0.5 30 m.12308A>G                            
m.15905C>T tRNAThr 
64 bvFTD M 65 63 1 29  
 
65 bvFTD F 77 64 1 21  
 
66 bvFTD M 70 67 1 25  
 
67 bvFTD M 70 68 1 22  
 
tRNAArg 68 bvFTD M 48 45 2 13 m.10463T>C 
m.15928C>A tRNAThr 
tRNALeu2 69 CBS F 62 60 1 20 m.12308A>G 
m.15905C>T tRNAThr 
70 bvFTD M 69 54 0.5 28  
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Table 3:  In silico analysis of the sequence variations found in mt-tRNA enconding genes. 
Minimum free energy 
(kcal/mol) Change of 
nucleotide Locus (tRNA) Reported in MITOMAP 
Frequency in the 
sample (n) Normal Changed 
Structure 
Localization in 
tRNA 
structure 
Evolutionary 
conservation 
m.1640A>G tRNAVal Polymorphism 1.429%(1) -12.5 -17.6 Changed Anticodon stem 90% 
m.1659T>C tRNAVal Mutation (Movement Disorder) 1.429%(1) -12.5 -10.7 Changed T-stem 60% 
m.4312 C>T tRNAIle Polymorphism Somatic Mutation 1.429%(1) -7.8 -8.5 Changed T-loop 80% 
m.4318C>T tRNAIle Polymorphism 1.429%(1) -7.8 -9.6 Changed T-loop 60% 
m.4336T>C tRNAGln 
Polymorphism                                                                                 
Mutation (ADPD/Hearing Loss & 
Migraine) 
1.429%(1) -19.5 -19.5 Normal Acceptor stem 70% 
m.4435A>G tRNAMet Polymorphism                                                                                                Mutation (LHON/hypertension) 1.429%(1) -12.8 -12.9 Changed Anticodon loop 100% 
m.4456C>T tRNAMet Polymorphism Mutation (Poss. hypertension factor) 1.429%(1) -12.8 -12.4 Changed T-loop 60% 
m.5633C>T tRNAAla Polymorphism Somatic Mutation 2.857%(2) -17 -16.7 Changed Anticodon stem 40% 
m.5772G>A tRNACys Polymorphism 1.429%(1) -18.1 -15.9 Changed T-stem 100% 
m.5775T>C tRNACys Polymorphism 1.429%(1) -18.1 -17.8 Normal T-loop 80% 
m.7521G>A tRNAAsp Polymorphism 1.429%(1) -9.1 -9.7 Normal Acceptor stem 50% 
m.7567C>A tRNAAsp Novel 1.429%(1) -9.1 -10.9 Changed T-loop 40% 
m.10034T>C tRNAGly Polymorphism 4.286%(3) -8.5 -8.1 Changed Variable region 90% 
m.10410T>C tRNAArg Polymorphism 1.429% (1) -10.1 -11.7 Normal Acceptor stem 20% 
m.10463T>C tRNAArg Polymorphism                                                                                                Somatic Mutation 2.8557%(2) -10.1 -10.1 Normal Acceptor stem 100% 
m.12166T>C tRNAHis Polymorphism 1.429%(1) -10 -9.5 Changed Anticodon loop 80% 
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Table 3:  In silico analysis of the sequence variations found in mt-tRNA enconding genes (cont.). 
m.12179A>G tRNAHis Polymorphism 1.429%(1) -10 -10 Normal Variable region 100% 
m.12184A>G tRNAHis Polymorphism 1.429%(1) -10 -15 Changed T-stem 70% 
m.12192G>A tRNAHis Polymorphism                                                                                                                           Mutation (MICM) 1.429%(1) -10 -9.9 Normal T-loop 30% 
m.12308A>G tRNALeu2 Polymorphism                                                                                                                                                                                                                                                   Somatic Mutation 14.286%(10) -15.1 -14.9 Changed Variable region 100% 
m.15904C>T tRNAThr Polymorphism 5.714%(4) -13.6 -13.3 Changed D-loop 60% 
m.15905C>T tRNAThr Polymorphism 4.286%(3) -13.6 -13.3 Changed D-loop 40% 
m.15908T>C tRNAThr Polymorphism Mutation (DEAF) 1.429%(1) -13.6 -13.6 Normal D-stem 100% 
m.15924A>G tRNAThr Polymorphism Mutation (LIMM) 4.286%(3) -13.6 -13.6 Normal Acceptor stem 100% 
m.15927G>A tRNAThr Polymorphism Mutation (Multiple Sclerosis/DEAF) 2.857%(2) -13.6 -13.4 Normal Acceptor stem 50% 
m.15928G>A tRNAThr 
Polymorphism 
Mutation (Multiple Sclerosis/idiopathic 
repeat miscarriage/AD) 
2.857%(2) -13.6 -13.6 Normal Acceptor stem 70% 
m.15930G>A tRNAThr Polymorphism 1.429%(1) -13.6 -11.2 Changed Variable region 20% 
m.15946C>T tRNAThr Polymorphism 1.429%(1) -13.6 -11.4 Changed Acceptor stem 80% 
 
Abbreviations: ADPD = Alzheimer's Disease and Parkinson Disease; LHON= Leber's Hereditary Optic Neuropathy ; MICM = Maternally Inherited Cardiomyopathy; DEAF= Deafness; 
LIMM=Mitochondrial Myopathy Lethal Infantile. 
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Figure 2: Results from in silico analysis for nucleotide (m.4312C>T mt-tRNAIle) A-
normal and B- “mutated” structure (RNAfold); C- Location of the sequence variation in 
the clover-shaped structure; D- Evolutionary conservation for the nucleotide position 
(signed with blue rectangle). 
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Figure 3: Results from in silico analysis for nucleotide (m.4435A>G of mt-tRNAMet) A-
normal and  B- “mutated” structure (RNAfold); C- Location of the sequence variation in 
the clover-shaped structure; D- Evolutionary conservation for the nucleotide position 
(signed with blue rectangle). 
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Figure 4: Results from in silico analysis for nucleotide (m.5772G>A of mt-tRNACys) A-
normal and B- “mutated” structure (RNAfold); C- Location of the sequence variation in 
the clover-shaped structure; D- Evolutionary conservation for the nucleotide position 
(signed with blue rectangle). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Results from in silico analysis for nucleotide (m.12166T>C of mt-tRNAHis) A-
normal and B- “mutated” structure (RNAfold); C- Location of the sequence variation in 
the clover-shaped structure; D- Evolutionary conservation for the nucleotide position 
(signed with blue rectangle). 
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Figure 6: Results from in silico analysis for nucleotide (m.12308A>G of mt-tRNALeu2) 
A-normal and B- “mutated” structure (RNAfold); C- Location of the sequence variation 
in the clover-shaped structure; D- Evolutionary conservation for the nucleotide position 
(signed with blue rectangle). 
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Figure 7:  Results from in silico analysis for nucleotide (m.15946C>T of mt-tRNAThr) 
A-normal and B- “mutated” structure (RNAfold); C- Location of the sequence variation 
in the clover-shaped structure; D- Evolutionary conservation for the nucleotide position 
(signed with blue rectangle). 
 
Discussion 
Human mitochondrial tRNAs acquired interest with the discovery of correlations 
between point mutations in its genes and neurodegenerative diseases (Zifa et al., 2007). 
The clinical evaluation related to mtDNA is often complicated and mt-tRNAs mutations 
present unusual difficulties in clinical diagnosis because of the inability to determine if 
the changes are pathogenic or not (Glatz et al., 2011). The minimum free energy is a 
criterion to predict the stability of mt-tRNA structure, since a pathogenic mutation in 
mt-tRNA can alter the secondary structure. Lower minimum free energy is related to a 
more stable structure, but it is not an absolute fact, because of biological complexity 
(Zhang et al., 2011). Evolutionary conservation is also an important feature of 
pathogenicity (Yarham et al., 2011). High percentage of evolutionary conservation 
suggests that sequence variation may be deleterious. In 28 variations, 17 (m.1640A>G, 
m.1659T>C, m4312C>T, m.4318C>T, m.4435A>G ,m.4456C>T, m.5633C>T, 
m.5772G<A, m.7567C>A, m.10034T>C, m.12166T>C, m.12184A>G, m.12308A>G, 
m.15904C>T, m.15905C>T, m.15930G>A and m.15946C>T) are predicted to have 
15946T 
(D) (C) 
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changes of structure and minimum free energy, but only 8 variations have an elevated 
evolutionary conservation (Table 3). In 5 variations, despite of having high percentage 
of conservation, its structures do not change (m.5775T>C, m.10463T>C, m.12179A>G, 
m.15908T>C and m.15924A>G). There are 7 alterations (m.1640A>G, m.5772G>A, 
m.5775T>C, m.10034T>C, m.12166 T>C, m.12179A>G and m.15946C>T) that are 
reported in MITOMAP as polymorphisms but the percentage of conservation is high. 
Variations previously described as pathogenic mutations, affect mostly high conserved 
nucleotides, whereas most polymorphic alterations affect rather nonconserved 
nucleotides (Table 3). However, there are exceptions: some pathogenic mutations affect 
nonconserved positions and some polymorphic variations affect conserved positions. 
This suggests that the rate of conservation of a nucleotide by itself cannot be considered 
as a threshold for which the mutation will be effectively pathogenic (Zifa et al., 2007). 
Other criteria must be considered. 
From the 28 variations detected, m.4312C>T, m.4318C>T and m.4456C>T are 
present in heteroplasmy, and were found in the same patient, but the percentage of 
heteroplasmy was not determined. On the other hand, heteroplasmy of variants in mt-
tRNA genes has been generally regarded as direct evidence for pathogenicity 
(McFarland et al., 2004). 
Location of variations in the tRNA structure is also very important. For a 
mutation affecting directly the function of mt-tRNA, this should occur in a critical base 
to the recognition of the codon and aminoacylation. However, of all the pathogenic 
mutations that occur in mt-tRNA genes and that have been previously associated with 
mitochondrial diseases, only a few occur in these critical positions (Suzuki et al., 2011). 
From 28 variations, there are 14 alterations that are located in the stems, 10 variations 
are localized in the loops and 4 are in the variable region. Many mt-tRNA pathological 
mutations are mainly located, on the stem portions (Pereira et al., 2008). An elevated 
number of variations were found in tRNAThr coding genes, in comparison with other 
tRNAs. This is in agreement to the study by Pereira and colleagues (2008), which 
indicates that the variability in this gene is much higher, especially in the stem regions. 
Other mt-tRNAs genes have also more variations in the stems, such as tRNAVal and 
tRNAArg. Other genes have higher numbers of variations in the loops (tRNAIle and 
tRNAMet). The tRNAMet presents variations in the loops, namely one substitution, 
m.4435A>G, is located in the anticodon loop, which is relevant, since this tRNA 
performs an important role as the initiator of all mtDNA proteins.  
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The breaking of Watson–Crick base pairing is an important characteristic to 
identify pathogenic mutations that occur in the stem structures. The disruption of C-G 
(cytosine-guanine) base pair linking is significantly more common in pathogenic 
mutations. The A–T (adenine–thymine) bonding has a lower thermodynamic energy 
than C–G bonding and it is possible that breaking A–T bonds has less effect on the 
structure of the mt-RNA than an equal break of a C–G pair bases (Figure 4 and 7)  
(McFarland et al., 2004). Variation m.5772G>A is in T-stem of tRNACys (within LS of 
mtDNA). Variations m.15927G>A, m.15928G>A and m.15946C>T are located in 
stems of tRNAThr. Since these variations break the links C-G, these changes are 
probably more pathogenic. 
After in silico analysis, there are 6 sequence variations that present high 
probability of being pathogenic:  m.4312C>T, due the heteroplasmy presented, to the 
change of minimum free energy and its structure, and high percentage of conservation; 
m.4435A>G alteration induces structure and binding minimum free energy changes, it 
is localized in a critical position and it is totally conserved in all species analysed; 
m.5772G>A modifies the structure and binding minimum free energy, being located a 
local of disruption of Watson–Crick base pairing (C-G) of T-stem and it is 100% 
conserved in all species; the alteration m.12166T>C presents changes in structure and 
binding minimum free energy, it is located in anticodon loop and is highly conserved; 
the most frequent variation identified in our cohort is m.12308A>G, in the variable 
region of mt-tRNALeu2 gene. This variation leads to structure alteration and it is totally 
conserved; the variation m.15946C>T also causes change in the structure and minimum 
free energy; it is localized in the acceptor stem and has high conservation rate. 
 
Conclusions 
The analysis of the mt-tRNAs variations indicates that there is not sufficient 
evidence to classify the variations as pathogenic causative of FTLD. However, through 
this study it is possible to gather important data. 
Most of the detected variations altered the structure and minimum free energy of 
tRNAs. There is a higher number of substitutions in the stems than in the loops, which 
is in agreement with the literature, concerning the involvement of mt-tRNA folding 
genes in diseases. The evolutionary conservation is not always in agreement with the 
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results obtained for the structure, for prediction of pathogenicity. Therefore, it is 
difficult to detect pathogenic mutations due to heterogeneity of results. Nevertheless, 
according to all the pathogenicity criteria studied, in 28 variations detected, the more 
likely to be pathogenic are m.4312C>T in tRNAIle, m.4435A>G in tRNAMet, 
m.5772G>A in tRNACys, m.12166T>C in tRNAHis, m.12308A>C in tRNALeu2 and 
m.15946C>T in tRNAThr. 
It is yet unclear, at the molecular level, how the mutant mt-tRNAs can cause 
mitochondrial dysfunction. There is a current notion that not only mt-tRNA mutations, 
but a combination of different mutations present in mitochondrial genes is responsible 
for a variety of clinical diseases (McFarland et al., 2004). 
Additionally, given the role of mt-tRNAs in MRC function, mutations in these 
genes may affect the ability to produce mitochondrial proteins. These protein synthesis 
anomalies result in OXPHOS deficiency, since the enzymatic activity of all MRC 
complexes could be affected. Furthermore, according to the “Mitochondrial cascade 
hypothesis” (Swerdlow and Khan, 2004), polymorphic variations in MCR subunits 
encoding genes establish MCR efficiency and basal mitochondrial ROS production, that 
correlates with mtDNA damage. Acordingly, somatic mtDNA mutation decreases MCR 
efficiency leading to reduced OXPHOS and/or increased ROS production. For this 
reason, mtDNA mutations possibly modify age of onset, contributing to 
neurodegeneration process, probably due to an impairment of MCR and/or translation 
mechanisms. 
Moreover, deeper biochemical investigations are needed to better understand the 
relationships between mtDNA and FTLD, considering the involvement of nuclear 
genes. Genotype/phenotype correlation can involve nuclear and mitochondrial 
interactions, but the exact mechanism is still unknown.  
In conclusion, more research is needed to determine whether the mt-tRNA 
variations play a direct pathogenic role in FTLD. A functional study would certainly 
help to prove the possible pathogenicity of these alterations. 
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http://www.elsevier.com/authorsrights.Open access articles please see 
http://www.elsevier.com/OAauthoragreement. 
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Role of the funding source 
You are requested to identify who provided financial support for the conduct of the 
research and/or preparation of the article and to briefly describe the role of the 
sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; 
in the writing of the report; and in the decision to submit the article for publication. If 
the funding source(s) had no such involvement then this should be stated. Please see 
http://www.elsevier.com/funding. 
 
Funding body agreements and policies 
Elsevier has established agreements and developed policies to allow authors whose 
articles appear in journals published by Elsevier, to comply with potential manuscript 
archiving requirements as specified as conditions of their grant awards. To learn more 
about existing agreements and policies please visit 
http://www.elsevier.com/fundingbodies. 
 
Open access 
This journal offers authors a choice in publishing their research: 
 
Open Access 
• Articles are freely available to both subscribers and the wider public with permitted 
reuse 
• An Open Access publication fee is payable by authors or their research funder 
Subscription 
• Articles are made available to subscribers as well as developing countries and patient 
groups through 
our access programs (http://www.elsevier.com/access) 
• No Open Access publication fee 
 
All articles published Open Access will be immediately and permanently free for 
everyone to read and download. Permitted reuse is defined by your choice of one of the 
following Creative Commons user licenses: 
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to 
create extracts, abstracts, and other revised versions, adaptations or derivative works of 
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or from an article (such as a translation), to include in a collective work (such as an 
anthology), to text or data mine the article, even for commercial purposes, as long as 
they credit the author(s), do not represent the author as endorsing their adaptation of the 
article, and do not modify the article in such a way as to damage the author's honor or 
reputation. 
Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA): for non-
commercial purposes, lets others distribute and copy the article, to create extracts, 
abstracts and other revised versions, adaptations or derivative works of or from an 
article (such as a translation), to include in a collective work (such as an anthology), to 
text and data mine the article, as long as they credit the author(s), do not represent the 
author as endorsing their adaptation of the article, do not modify the article in such a 
way as to damage the author's honor or reputation, and license their new adaptations or 
creations under identical terms (CC BY-NC-SA). 
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND): for non-
commercial purposes, lets others distribute and copy the article, and to include in a 
collective work (such as an anthology), as long as they credit the author(s) and provided 
they do not alter or modify the article. 
To provide Open Access, this journal has a publication fee which needs to be met by the 
authors or their research funders for each article published Open Access. 
Your publication choice will have no effect on the peer review process or acceptance of 
submitted articles. 
 
The publication fee for this journal is $2200, excluding taxes. Learn more about 
Elsevier's pricing policy: http://www.elsevier.com/openaccesspricing. 
 
Language (usage and editing services) 
Please write your text in good English (American or British usage is accepted, but not a 
mixture of these). Authors who feel their English language manuscript may require 
editing to eliminate possible grammatical or spelling errors and to conform to correct 
scientific English may wish to use the English Language Editing service available from 
Elsevier's WebShop http://webshop.elsevier.com/languageediting/ or visit our customer 
support site http://support.elsevier.com for more information. 
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Submission to this journal proceeds totally online and you will be guided stepwise 
through the creation and uploading of your files. The system automatically converts 
source files to a single PDF file of the article, which is used in the peer-review process. 
Please note that even though manuscript source files are converted to PDF files at 
submission for the review process, these source files are needed for further processing 
after acceptance. All correspondence, including notification of the Editor's decision and 
requests for revision, takes place by e-mail removing the need for a paper trail. 
 
Referees 
Please submit, with the manuscript, the names, addresses and e-mail addresses of three 
potential referees. Note that the editor retains the sole right to decide whether or not the 
suggested reviewers are used. 
 
PREPARATION 
 
Use of wordprocessing software 
It is important that the file be saved in the native format of the wordprocessor used. The 
text should be in single-column format. Keep the layout of the text as simple as 
possible. Most formatting codes will be removed and replaced on processing the article. 
In particular, do not use the wordprocessor's options to justify text or to hyphenate 
words. However, do use bold face, italics, subscripts, superscripts etc. When preparing 
tables, if you are using a table grid, use only one grid for each individual table and not a 
grid for each row. If no grid is used, use tabs, not spaces, to align columns. The 
electronic text should be prepared in a way very similar to that of conventional 
manuscripts 
(see also the Guide to Publishing with Elsevier: 
http://www.elsevier.com/guidepublication). Note that source files of figures, tables and 
text graphics will be required whether or not you embed your figures in the text. See 
also the section on Electronic artwork. To avoid unnecessary errors you are strongly 
advised to use the 'spell-check' and 'grammar-check' functions of your wordprocessor. 
 
Article structure 
Subdivision - unnumbered sections 
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Divide your article into clearly defined sections. Each subsection is given a brief 
heading. Each heading should appear on its own separate line. Subsections should be 
used as much as possible when crossreferencing text: refer to the subsection by heading 
as opposed to simply 'the text'. 
 
Introduction 
State the objectives of the work and provide an adequate background, avoiding a 
detailed literaturesurvey or a summary of the results. 
 
Material and methods 
Provide sufficient detail to allow the work to be reproduced. Methods already published 
should be indicated by a reference: only relevant modifications should be described. 
 
Results 
Results should be clear and concise. 
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Discussion 
This should explore the significance of the results of the work, not repeat them. A 
combined Results and Discussion section is often appropriate. Avoid extensive citations 
and discussion of published literature. 
 
Conclusions 
The main conclusions of the study may be presented in a short Conclusions section, 
which may standalone or form a subsection of a Discussion or Results and Discussion 
section. 
 
Appendices 
If there is more than one appendix, they should be identified as A, B, etc. Formulae and 
equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; 
in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table 
A.1; Fig. A.1,etc. 
 
Essential title page information 
 Isabel Oliveira Page 51 
 
• Title. Concise and informative. Titles are often used in information-retrieval systems. 
Avoid abbreviations and formulae where possible. 
• Author names and affiliations. Where the family name may be ambiguous (e.g., a 
double name), please indicate this clearly. Present the authors' affiliation addresses 
(where the actual work was done) below the names. Indicate all affiliations with a 
lower-case superscript letter immediately after the author's name and in front of the 
appropriate address. Provide the full postal address of each affiliation, including the 
country name and, if available, the e-mail address of each author. 
• Corresponding author. Clearly indicate who will handle correspondence at all stages 
of refereeing and publication, also post-publication. Ensure that phone numbers (with 
country and area code) are provided in addition to the e-mail address and the complete 
postal address. Contact details must be kept up to date by the corresponding author. 
• Present/permanent address. If an author has moved since the work described in the 
article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') 
may be indicated as a footnote to that author's name. The address at which the author 
actually did the work must be retained as the main, affiliation address. Superscript 
Arabic numerals are used for such footnotes. 
 
Abstract 
A concise and factual abstract is required. The abstract should state briefly the purpose 
of the research, the principal results and major conclusions. An abstract is often 
presented separately from the article, so it must be able to stand alone. For this reason, 
References should be avoided, but if essential, then cite the author(s) and year(s). Also, 
non-standard or uncommon abbreviations should be avoided, but if essential they must 
be defined at their first mention in the abstract itself. 
 
Graphical abstract 
A Graphical abstract is optional and should summarize the contents of the article in a 
concise, pictorial form designed to capture the attention of a wide readership online. 
Authors must provide images that clearly represent the work described in the article. 
Graphical abstracts should be submitted as a separate file in the online submission 
system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × 
w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a 
regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office 
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files. See http://www.elsevier.com/graphicalabstracts for examples. Authors can make 
use of Elsevier's Illustration and Enhancement service to ensure the best presentation of 
their images also in accordance with all technical requirements: Illustration Service. 
 
Highlights 
Highlights are mandatory for this journal. They consist of a short collection of bullet 
points that convey the core findings of the article and should be submitted in a separate 
file in the online submission system. Please use 'Highlights' in the file name and include 
3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). See 
http://www.elsevier.com/highlights for examples. 
 
Keywords 
Immediately after the abstract, provide a maximum of 10 keywords, using American 
spelling and avoiding general and plural terms and multiple concepts (avoid, for 
example, "and", "of"). Be sparing with abbreviations: only abbreviations firmly 
established in the field may be eligible. These keywords will be used for indexing 
purposes. 
 
Abbreviations 
Define abbreviations that are not standard in this field in a footnote to be placed on the 
first page of the article. Such abbreviations that are unavoidable in the abstract must be 
defined at their first mention there, as well as in the footnote. Ensure consistency of 
abbreviations throughout the article. 
 
Acknowledgements 
Collate acknowledgements in a separate section at the end of the article before the 
references and do not, therefore, include them on the title page, as a footnote to the title 
or otherwise. List here those individuals who provided help during the research (e.g., 
providing language help, writing assistance or proof reading the article, etc.). 
 
Units 
Follow internationally accepted rules and conventions: use the international system of 
units (SI). If other units are mentioned, please give their equivalent in SI. 
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Database linking 
Elsevier encourages authors to connect articles with external databases, giving their 
readers one-click access to relevant databases that help to build a better understanding 
of the described research. 
Please refer to relevant database identifiers using the following format in your article: 
Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). See 
http://www.elsevier.com/databaselinking for more information and a full list of 
supported databases. 
 
Footnotes 
Footnotes should be used sparingly. Number them consecutively throughout the article, 
using superscript Arabic numbers. Many wordprocessors build footnotes into the text, 
and this feature may be used. Should this not be the case, indicate the position of 
footnotes in the text and present the footnotes themselves separately at the end of the 
article. Do not include footnotes in the Reference list. 
Table footnotes 
Indicate each footnote in a table with a superscript lowercase letter. 
 
Artwork 
Electronic artwork 
General points 
• Make sure you use uniform lettering and sizing of your original artwork. 
• Embed the used fonts if the application provides that option. 
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New 
Roman, Symbol, or use fonts that look similar. 
• Number the illustrations according to their sequence in the text. 
• Use a logical naming convention for your artwork files. 
• Provide captions to illustrations separately. 
• Size the illustrations close to the desired dimensions of the printed version. 
• Submit each illustration as a separate file. 
A detailed guide on electronic artwork is available on our website: 
http://www.elsevier.com/artworkinstructions 
You are urged to visit this site; some excerpts from the detailed information are given 
here. 
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Formats 
If your electronic artwork is created in a Microsoft Office application (Word, 
PowerPoint, Excel) then please supply 'as is' in the native document format. 
Regardless of the application used other than Microsoft Office, when your electronic 
artwork is finalized, please 'Save as' or convert the images to one of the following 
formats (note the resolution requirements for line drawings, halftones, and line/halftone 
combinations given below): EPS (or PDF): Vector drawings, embed all used fonts. 
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 
dpi. TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a 
minimum of 1000 dpi. TIFF (or JPEG): Combinations bitmapped line/half-tone (color 
or grayscale), keep to a minimum of 500 dpi. 
Please do not: 
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these 
typically have a low number of pixels and limited set of colors; 
• Supply files that are too low in resolution; 
• Submit graphics that are disproportionately large for the content. 
 
Color artwork 
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS 
(or PDF) or MS Office files) and with the correct resolution. If, together with your 
accepted article, you submit usable color figures then Elsevier will ensure, at no 
additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect 
and other sites) in addition to color reproduction in print. For further information on the 
preparation of electronic artwork, please see 
http://www.elsevier.com/artworkinstructions. 
 
Illustration services 
Elsevier's WebShop (http://webshop.elsevier.com/illustrationservices) offers Illustration 
Services to authors preparing to submit a manuscript but concerned about the quality of 
the images accompanying their article. Elsevier's expert illustrators can produce 
scientific, technical and medicalstyle images, as well as a full range of charts, tables and 
graphs. Image 'polishing' is also available, where our illustrators take your image(s) and 
improve them to a professional standard. Please visit the website to find out more. 
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Figure captions 
Ensure that each illustration has a caption. Supply captions separately, not attached to 
the figure. A caption should comprise a brief title (not on the figure itself) and a 
description of the illustration. Keep text in the illustrations themselves to a minimum 
but explain all symbols and abbreviations used. 
 
Tables 
Number tables consecutively in accordance with their appearance in the text. Place 
footnotes to tables below the table body and indicate them with superscript lowercase 
letters. Avoid vertical rules. Besparing in the use of tables and ensure that the data 
presented in tables do not duplicate results described elsewhere in the article. 
 
References 
Citation in text 
Please ensure that every reference cited in the text is also present in the reference list 
(and vice versa). Any references cited in the abstract must be given in full. Unpublished 
results and personal communications are not recommended in the reference list, but may 
be mentioned in the text. If these references are included in the reference list they 
should follow the standard reference style of the journal and should include a 
substitution of the publication date with either 'Unpublished results' or 'Personal 
communication'. Citation of a reference as 'in press' implies that the item has been 
accepted for publication. 
 
Web references 
As a minimum, the full URL should be given and the date when the reference was last 
accessed. Any further information, if known (DOI, author names, dates, reference to a 
source publication, etc.), should also be given. Web references can be listed separately 
(e.g., after the reference list) under a different heading if desired, or can be included in 
the reference list. 
 
References in a special issue 
Please ensure that the words 'this issue' are added to any references in the list (and any 
citations in the text) to other articles in the same Special Issue. 
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Reference style 
Text: All citations in the text should refer to: 
1. Single author: the author's name (without initials, unless there is ambiguity) and the 
year of publication; 
2. Two authors: both authors' names and the year of publication; 
3. Three or more authors: first author's name followed by 'et al.' and the year of 
publication. Citations may be made directly (or parenthetically). Groups of references 
should be listed first alphabetically, then chronologically. 
Examples: 'as demonstrated in wheat (Allan, 2000a, 2000b, 1999; Allan and Jones, 
1999). Kramer et al. (2010) have recently shown ....' 
List: References should be arranged first alphabetically and then further sorted 
chronologically if necessary. More than one reference from the same author(s) in the 
same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of 
publication. 
Examples: 
Reference to a journal publication: 
Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci 
Commun2010; 163 : 51–9. 
Reference to a book: 
Strunk Jr W, White EB. The elements of style. 4th ed. New York: Longman; 2000. 
Reference to a chapter in an edited book: 
Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones 
BS, Smith RZ,editors. Introduction to the electronic age. New York: E-Publishing Inc; 
2009. p. 281–304. Note shortened form for last page number. e.g., 51–9, and that for 
more than 6 authors the first 6 should be listed followed by "et al." For further details 
you are referred to "Uniform Requirements for Manuscripts submitted to Biomedical 
Journals" (J Am Med Assoc 1997; 277 : 927–34) (see also 
http://www.nlm.nih.gov/bsd/uniform_requirements.html). 
 
Journal abbreviations source 
Journal names should be abbreviated according to: 
List of title word abbreviations: http://www.issn.org/2-22661-LTWA-online.php; NLM 
Catalog (Journals referenced in the NCBI Databases): 
http://www.ncbi.nlm.nih.gov/nlmcatalog/journals; 
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CAS (Chemical Abstracts Service): via 
http://www.cas.org/content/references/corejournals. 
 
Video data 
Elsevier accepts video material and animation sequences to support and enhance your 
scientific research. Authors who have video or animation files that they wish to submit 
with their article are strongly encouraged to include links to these within the body of the 
article. This can be done in the same way as a figure or table by referring to the video or 
animation content and noting in the body text where it should be placed. All submitted 
files should be properly labeled so that they directly relate to the video file's content. In 
order to ensure that your video or animation material is directly usable, please provide 
the files in one of our recommended file formats with a preferred maximum size of 50 
MB. Video and animation files supplied will be published online in the electronic 
version of your article in Elsevier Web products, including ScienceDirect: 
http://www.sciencedirect.com. Please supply 'stills' with your files: you can choose any 
frame from the video or animation or make a separate image. These will be used instead 
of standard icons and will personalize the link to your video data. For more detailed 
instructions please visit our video instruction pages at 
http://www.elsevier.com/artworkinstructions. Note: since video and animation cannot 
be embedded in the print version of the journal, please provide text for both the 
electronic and the print version for the portions of the article that refer to this content. 
 
AudioSlides 
The journal encourages authors to create an AudioSlides presentation with their 
published article. AudioSlides are brief, webinar-style presentations that are shown next 
to the online article on ScienceDirect. This gives authors the opportunity to summarize 
their research in their own words and to help readers understand what the paper is about. 
More information and examples are available athttp://www.elsevier.com/audioslides. 
Authors of this journal will automatically receive an invitation e-mail to create an 
AudioSlides presentation after acceptance of their paper. 
 
Supplementary data 
Elsevier accepts electronic supplementary material to support and enhance your 
scientific research. Supplementary files offer the author additional possibilities to 
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publish supporting applications, high resolution images, background datasets, sound 
clips and more. Supplementary files supplied will be published online alongside the 
electronic version of your article in Elsevier Web products, including ScienceDirect: 
http://www.sciencedirect.com. In order to ensure that your submitted material is directly 
usable, please provide the data in one of our recommended file formats. Authors should 
submit the material in electronic format together with the article and supply a concise 
and descriptive caption for each file. For more detailed instructions please visit our 
artwork instruction pages at http://www.elsevier.com/artworkinstructions. 
 
Submission checklist 
The following list will be useful during the final checking of an article prior to sending 
it to the journal for review. Please consult this Guide for Authors for further details of 
any item. 
Ensure that the following items are present: 
One author has been designated as the corresponding author with contact details: 
• E-mail address 
• Full postal address 
• Phone numbers 
All necessary files have been uploaded, and contain: 
• Keywords 
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• All figure captions 
• All tables (including title, description, footnotes) 
Further considerations 
• Manuscript has been 'spell-checked' and 'grammar-checked' 
• References are in the correct format for this journal 
• All references mentioned in the Reference list are cited in the text, and vice versa 
• Permission has been obtained for use of copyrighted material from other sources 
(including the Web) 
• Color figures are clearly marked as being intended for color reproduction on the Web 
(free of charge) and in print, or to be reproduced in color on the Web (free of charge) 
and in black-and-white in print 
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• If only color on the Web is required, black-and-white versions of the figures are also 
supplied for printing purposes.For any further information please visit our customer 
support site at http://support.elsevier.com. 
 
AFTER ACCEPTANCE 
Use of the Digital Object Identifier 
The Digital Object Identifier (DOI) may be used to cite and link to electronic 
documents. The DOI consists of a unique alpha-numeric character string which is 
assigned to a document by the publisher upon the initial electronic publication. The 
assigned DOI never changes. Therefore, it is an ideal medium for citing a document, 
particularly 'Articles in press' because they have not yet received their full bibliographic 
information. Example of a correctly given DOI (in URL format; here an article in the 
journal Physics Letters B): http://dx.doi.org/10.1016/j.physletb.2010.09.059  
When you use a DOI to create links to documents on the web, the DOIs are guaranteed 
never to change. 
 
Proofs 
One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author 
(if we do not have an e-mail address then paper proofs will be sent by post) or, a link 
will be provided in the e-mail so that authors can download the files themselves. 
Elsevier now provides authors with PDF proofs which can be annotated; for this you 
will need to download Adobe Reader version 7 (or higher) available free from 
http://get.adobe.com/reader. Instructions on how to annotate PDF files will accompany 
the proofs (also given online). The exact system requirements are given at the Adobe 
site: http://www.adobe.com/products/reader/tech-specs.html. If you do not wish to use 
the PDF annotations function, you may list the corrections (including replies to the 
Query Form) and return them to Elsevier in an e-mail. Please list your corrections 
quoting line number. If, for any reason, this is not possible, then mark the corrections 
and any other comments (including replies to the Query Form) on a printout of your 
proof and return by fax, or scan the pages and e-mail, or by post. Please use this proof 
only for checking the typesetting, editing, completeness and correctness of the text, 
tables and figures. Significant changes to the article as accepted for publication will 
only be considered at this stage with permission from the Editor. We will do everything 
possible to get your article published quickly and accurately – please let us have all your 
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corrections within 48 hours. It is important to ensure that all corrections are sent back to 
us in one communication: please check carefully before replying, as inclusion of any 
subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. 
Note that Elsevier may proceed with the publication of your article if no response is 
received. 
 
Offprints 
The corresponding author, at no cost, will be provided with a PDF file of the article via 
email (the PDF file is a watermarked version of the published article and includes a 
cover sheet with the journal cover image and a disclaimer outlining the terms and 
conditions of use). For an extra charge, paper offprints can be ordered via the offprint 
order form which is sent once the article is accepted for publication. Both corresponding 
and co-authors may order offprints at any time via Elsevier's WebShop 
(http://webshop.elsevier.com/myarticleservices/offprints). Authors requiring printed 
copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service 
to collate multiple articles within a single cover 
(http://webshop.elsevier.com/myarticleservices/offprints/myarticlesservices/booklets). 
 
AUTHOR INQUIRIES 
For inquiries relating to the submission of articles (including electronic submission) 
please visit this journal's homepage. For detailed instructions on the preparation of 
electronic artwork, please visit http://www.elsevier.com/artworkinstructions. Contact 
details for questions arising after acceptance of an article, especially those relating to 
proofs, will be provided by the publisher. You can track accepted articles at 
http://www.elsevier.com/trackarticle. You can also check our Author FAQs at 
http://www.elsevier.com/authorFAQ and/or contact Customer Support via 
http://support.elsevier.com. 
 
